Patent Expiry

Patent/Exclusivity Expiry: OFIRMEV

Other upcoming events for GPCR

Phase 2 ReadoutPhase 2 Readout: aleniglipron
Patent ExpiryPatent/Exclusivity Expiry: LEGUBETI
Phase 3 ReadoutPhase 3 Topline: IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Patent ExpiryPatent/Exclusivity Expiry: ACETAMINOPHEN
Patent ExpiryPatent/Exclusivity Expiry: APADAZ

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: OFIRMEV — GPCR Patent Expiry | BioSniper